Management of cSSTIs: The role of daptomycin

Current Medical Research and Opinion

Volumn 22, Issue 11, 2006, Pages 2079-2087

  Garau, Javier ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Anti bacterial agent; cSSTIs; Daptomycin; Enterococci; Methicillin resistance; Staphylococcus aureus; Vancomycin resistance

Indexed keywords

AMPICILLIN; CEFTRIAXONE; CLOXACILLIN; DALFOPRISTIN; DAPTOMYCIN; FLUCLOXACILLIN; GENTAMICIN; HABEKACIN; LINEZOLID; NAFCILLIN; OXACILLIN; PENICILLIN G; PHOSPHOTRANSFERASE; QUINUPRISTIN; RIFAMPICIN; VANCOMYCIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ANAPHYLAXIS; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHILIA; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERSENSITIVITY; IN VITRO STUDY; INFECTION COMPLICATION; LIVER DYSFUNCTION; MEDICAL LITERATURE; MINIMUM INHIBITORY CONCENTRATION; MUSCLE DISEASE; PROSTHESIS INFECTION; RHABDOMYOLYSIS; SHORT SURVEY; SKIN INFECTION; SOFT TISSUE INFECTION; TREATMENT DURATION;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; TREATMENT OUTCOME;

EID: 33751208599     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X148292     Document Type: Short Survey

References (64)

1. Doern GV, Jones RN, Pfaller MA, et al. Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). SENTRY Study Group (North America). Diagn Microbiol Infect Dis 1999;34:65-72
2. Lewis RT. Soft tissue infections. World J Surg 1998;22:146-51
3. DiNubile MJ, Lipsky BA. Complicated infections of skin and skin structures: when the infection is more than skin deep. J Antimicrob Chemother 2004;53(Suppl 2):ii37-50
4. Menichetti F. Current and emerging serious Gram-positive infections. Clin Microbiol Infect 2005;11(Suppl 3):22-8
5. Barry AL, Fuchs PC, Brown SD. In vitro activities of daptomycin against 2789 clinical isolates from 11 North American medical centers. Antimicrob Agents Chemother 2001;45:1919-22
6. Critchley IA, Draghi DC, Sahm DF, et al. Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001. J Antimicrob Chemother 2003;51:639-49
7. Fluit AC, Schmitz FJ, Verhoef J, et al. Daptomycin in vitro susceptibility in European Gram-positive clinical isolates. Int J Antimicrob Agents 2004;24:59-66
8. Fluit AC, Schmitz FJ, Verhoef J, et al. In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants. Antimicrob Agents Chemother 2004;48:1007-11
9. Petersen PJ, Bradford PA, Weiss WJ, et al. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens. Antimicrob Agents Chemother 2002;46:2595-601
10. Richter SS, Kealey DE, Murray CT, et al. The in vitro activity of daptomycin against Staphylococcus aureus and Enterococcus species. J Antimicrob Chemother 2003;52:123-7
11. Rybak MJ, Hershberger E, Moldovan T, et al. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 2000;44:1062-6
12. Snydman DR, Jacobus NV, McDermott LA, et al. Comparative in vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens. Antimicrob Agents Chemother 2000;44:3447-50
13. Streit JM, Jones RN, Sader HS. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms. J Antimicrob Chemother 2004;53:669-74
14. Oleson FB, Jr., Berman CL, Kirkpatrick JB, et al. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 2000;44:2948-53
15. Jung D, Rozek A, Okon M, et al. Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin. Chem Biol 2004;11:949-57
16. Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 2003;47:2538-44
17. Sader HS, Streit JM, Fritsche TR, et al. Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwide. Diagn Microbiol Infect Dis 2004;50:201-4
18. Fuchs PC, Barry AL, Brown SD. In vitro bactericidal activity of daptomycin against staphylococci. J Antimicrob Chemother 2002;49:467-70
19. Lamp KC, Rybak MJ, Bailey EM, et al. In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin. Antimicrob Agents Chemother 1992;36:2709-14
20. LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2004;48:4665-72
21. Tedesco KL, Rybak MJ. Daptomycin. Pharmacotherapy 2004;24:41-57
22. Silverman JA, Oliver N, Andrew T, et al. Resistance studies with daptomycin. Antimicrob Agents Chemother 2001;45:1799-802
23. Hirschwerk D, Ginocchio CC, Bythrow M, et al. Diminished susceptibility to daptomycin accompanied by clinical failure in a patient with methicillin-resistant Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 2006;27:315-7
24. Marty FM, Yeh WW, Wennersten CB, et al. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol 2006;44:595-7
25. Skiest DJ. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 2006;44:655-6
26. Hayden MK, Rezai K, Hayes RA, et al. Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2005;43:5285-7
27. Vikram HR, Havill NL, Koeth LM, et al. Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin. J Clin Microbiol 2005;43:5384-7
28. Mangili A, Bica I, Snydman DR, et al. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2005;40:1058-60
29. Dandekar PK, Tessier PR, Williams P, et al. Determination of the pharmacodynamic profile of daptomycin against Streptococcus pneumoniae isolates with varying susceptibility to penicillin in a murine thigh infection model. Chemotherapy 2004;50:11-6
30. Dandekar PK, Tessier PR, Williams P, et al. Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. J Antimicrob Chemother 2003;52:405-11
31. Louie A, Kaw P, Liu W, et al. Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother 2001;45:845-51
32. Dvorchik BH, Brazier D, DeBruin MF, et al. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003;47:1318-23
33. Steenbergen JN, Alder J, Thorne GM, et al. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother 2005;55:283-8
34. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 2004;38:994-1000
35. Eisenstein BI. Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections. Expert Opin Investig Drugs 2004;13:1159-69
36. Tsuji BT, Rybak MJ, Rhomberg PR, et al. Evaluation of daptomycin, telavancin, and vancomycin activity in the presence of albumin or serum. Presented at 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, 16-19 December 2005
37. Craig WA, Kiem S, Andes DR. Effect of protein binding on the antimicrobial activity of daptomycin in sera and albumin solution. Presented at the 42nd Annual Meeting of the Infectious Diseases Society of America, Boston, MA, 30 September-3 October 2004
38. Woodworth JR, Nyhart EH, Jr., Brier GL, et al. Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother 1992;36:318-25
39. Dvorchik B. Moderate liver impairment has no influence on daptomycin pharmacokinetics. J Clin Pharmacol 2004;44:715-22
40. Dvorchik B, Damphousse D. Single-dose pharmacokinetics of daptomycin in young and geriatric volunteers. J Clin Pharmacol 2004;44:612-20
41. Cubicin Summary of Product Characteristics 2006. Available from http://www.emea.eu.int/humandocs/Humans/EPAR/ cubicin/cubicin.htm [Last accessed 23rd June 2006]
42. Dvorchik BH, Damphousse D. The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. J Clin Pharmacol 2005;45:48-56
43. Oleson FB, Berman CL, Li AP. An evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytes. Chem Biol Interact 2004;150:137-47
44. Tally FP, Zeckel M, Wasilewski MM, et al. Daptomycin: a novel agent for Gram-positive infections. Expert Opin Investig Drugs 1999;8:1223-38
45. Woodworth JR, Nyhart EH, Wolny JD, et al. Tobramycin and daptomycin disposition when co-administered to healthy volunteers. J Antimicrob Chemother 1994;33:655-9
46. LaPlante KL, Rybak MJ. Daptomycin - a novel antibiotic against Gram-positive pathogens. Expert Opin Pharmacother 2004;5:2321-31
47. Fowler VG, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355:653-65
48. Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004;38:1673-81
49. Chiron DAP data on file 003
50. Matthews PA, DeBruin MF. Faster resolution of clinical signs (CSx) in complicated skin and soft tissue infection (cSSTI) by daptomycin (DAP) vs. standard therapy (STND) in a randomized, blinded, comparative study. Presented at 39th Annual Meeting of the Infectious Diseases Society of America, San Francisco, California, USA, 25-28 October 2001
51. Owens RC, Lamp KC, Russo R, et al. Post marketing experience with daptomycin (DAP) for the treatment of skin and skin structure infections (SSSI). Presented at 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, USA, 16-19 December 2005
52. Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005;191:2149-52
53. Segreti JA, Crank CW, Finney MS. Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients. Pharmacotherapy 2006;26:347-52
54. von Eiff C, Jansen B, Kohnen W, et al. Infections associated with medical devices: pathogenesis, management and prophylaxis. Drugs 2005;65:179-214
55. Vaudaux P, Francois P, Bisognano C, et al. Comparative efficacy of daptomycin and vancomycin in the therapy of experimental foreign body infection due to Staphylococcus aureus. J Antimicrob Chemother 2003;52:89-95
56. Schaad HJ, Bento M, Lew DP, et al. Evaluation of high-dose daptomycin for therapy of experimental Staphylococcus aureus foreign body infection. BMC Infect Dis 2006;6:74
57. Rao N, Regalla DM. Uncertain efficacy of daptomycin for prosthetic joint infections. Clin Orthop Relat Res 2006; May 25 [Epub ahead of print]
58. Tsuji BT, Rybak MJ. Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2006;49:2735-45
59. Sakoulas G, Eliopoulos GM, Alder J, et al. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003;47:1714-8
60. Rand KH, Houck H. Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci. J Antimicrob Chemother 2004;53:530-2
61. Bingen E, Lambert-Zechovsky N, Leclercq R, et al. Bactericidal activity of vancomycin, daptomycin, ampicillin and amino-glycosides against vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother 1990;26:619-26
62. Akins RL, Rybak MJ. In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model. Antimicrob Agents Chemother 2000;44:1925-9
63. Burns CA. Daptomycin-rifampin for a recurrent MRSA joint infection unresponsive to vancomycin-based therapy. Scand J Infect Dis 2006;38:133-6
64. European Public Assessment Report for CUBICIN. Available from http://www.emea.eu.int/humandocs/Humans/EPAR/ cubicin/cubicin.htm [Last accessed 23rd June 2006]